Cargando…

The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces

The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy for hemophilia A patients, or they may sponta...

Descripción completa

Detalles Bibliográficos
Autores principales: Brison, Caileen M., Mullen, Steven M., Wuerth, Michelle E., Podolsky, Kira, Cook, Matthew, Herman, Jacob A., Walter, Justin D., Meeks, Shannon L., Spiegel, P. Clint
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361576/
https://www.ncbi.nlm.nih.gov/pubmed/25775247
http://dx.doi.org/10.1371/journal.pone.0122447
_version_ 1782361660419211264
author Brison, Caileen M.
Mullen, Steven M.
Wuerth, Michelle E.
Podolsky, Kira
Cook, Matthew
Herman, Jacob A.
Walter, Justin D.
Meeks, Shannon L.
Spiegel, P. Clint
author_facet Brison, Caileen M.
Mullen, Steven M.
Wuerth, Michelle E.
Podolsky, Kira
Cook, Matthew
Herman, Jacob A.
Walter, Justin D.
Meeks, Shannon L.
Spiegel, P. Clint
author_sort Brison, Caileen M.
collection PubMed
description The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy for hemophilia A patients, or they may spontaneously arise in cases of acquired hemophilia. Porcine factor VIII is an effective therapeutic for hemophilia patients with inhibitor due to its low cross-reactivity; however, the molecular basis for this behavior is poorly understood. In this study, the X-ray crystal structure of the porcine factor VIII C2 domain was determined, and superposition of the human and porcine C2 domains demonstrates that most surface-exposed differences cluster on the face harboring the “non-classical” antibody epitopes. Furthermore, antibody-binding results illustrate that the “classical” 3E6 antibody can bind both the human and porcine C2 domains, although the inhibitory titer to human factor VIII is 41 Bethesda Units (BU)/mg IgG versus 0.8 BU/mg IgG to porcine factor VIII, while the non-classical G99 antibody does not bind to the porcine C2 domain nor inhibit porcine factor VIII activity. Further structural analysis of differences between the electrostatic surface potentials suggest that the C2 domain binds to the negatively charged phospholipid surfaces of activated platelets primarily through the 3E6 epitope region. In contrast, the G99 face, which contains residue 2227, should be distal to the membrane surface. Phospholipid binding assays indicate that both porcine and human factor VIII C2 domains bind with comparable affinities, and the human K2227A and K2227E mutants bind to phospholipid surfaces with similar affinities as well. Lastly, the G99 IgG bound to PS-immobilized factor VIII C2 domain with an apparent dissociation constant of 15.5 nM, whereas 3E6 antibody binding to PS-bound C2 domain was not observed.
format Online
Article
Text
id pubmed-4361576
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43615762015-03-23 The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces Brison, Caileen M. Mullen, Steven M. Wuerth, Michelle E. Podolsky, Kira Cook, Matthew Herman, Jacob A. Walter, Justin D. Meeks, Shannon L. Spiegel, P. Clint PLoS One Research Article The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy for hemophilia A patients, or they may spontaneously arise in cases of acquired hemophilia. Porcine factor VIII is an effective therapeutic for hemophilia patients with inhibitor due to its low cross-reactivity; however, the molecular basis for this behavior is poorly understood. In this study, the X-ray crystal structure of the porcine factor VIII C2 domain was determined, and superposition of the human and porcine C2 domains demonstrates that most surface-exposed differences cluster on the face harboring the “non-classical” antibody epitopes. Furthermore, antibody-binding results illustrate that the “classical” 3E6 antibody can bind both the human and porcine C2 domains, although the inhibitory titer to human factor VIII is 41 Bethesda Units (BU)/mg IgG versus 0.8 BU/mg IgG to porcine factor VIII, while the non-classical G99 antibody does not bind to the porcine C2 domain nor inhibit porcine factor VIII activity. Further structural analysis of differences between the electrostatic surface potentials suggest that the C2 domain binds to the negatively charged phospholipid surfaces of activated platelets primarily through the 3E6 epitope region. In contrast, the G99 face, which contains residue 2227, should be distal to the membrane surface. Phospholipid binding assays indicate that both porcine and human factor VIII C2 domains bind with comparable affinities, and the human K2227A and K2227E mutants bind to phospholipid surfaces with similar affinities as well. Lastly, the G99 IgG bound to PS-immobilized factor VIII C2 domain with an apparent dissociation constant of 15.5 nM, whereas 3E6 antibody binding to PS-bound C2 domain was not observed. Public Library of Science 2015-03-16 /pmc/articles/PMC4361576/ /pubmed/25775247 http://dx.doi.org/10.1371/journal.pone.0122447 Text en © 2015 Brison et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Brison, Caileen M.
Mullen, Steven M.
Wuerth, Michelle E.
Podolsky, Kira
Cook, Matthew
Herman, Jacob A.
Walter, Justin D.
Meeks, Shannon L.
Spiegel, P. Clint
The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title_full The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title_fullStr The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title_full_unstemmed The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title_short The 1.7 Å X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
title_sort 1.7 å x-ray crystal structure of the porcine factor viii c2 domain and binding analysis to anti-human c2 domain antibodies and phospholipid surfaces
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361576/
https://www.ncbi.nlm.nih.gov/pubmed/25775247
http://dx.doi.org/10.1371/journal.pone.0122447
work_keys_str_mv AT brisoncaileenm the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT mullenstevenm the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT wuerthmichellee the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT podolskykira the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT cookmatthew the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT hermanjacoba the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT walterjustind the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT meeksshannonl the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT spiegelpclint the17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT brisoncaileenm 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT mullenstevenm 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT wuerthmichellee 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT podolskykira 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT cookmatthew 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT hermanjacoba 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT walterjustind 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT meeksshannonl 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces
AT spiegelpclint 17axraycrystalstructureoftheporcinefactorviiic2domainandbindinganalysistoantihumanc2domainantibodiesandphospholipidsurfaces